These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27633058)

  • 21. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
    Hao J; Madigan MC; Khatri A; Power CA; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley JH; Li Y
    PLoS One; 2012; 7(8):e40716. PubMed ID: 22870202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21.
    Zhou B; Wang J; Zheng G; Qiu Z
    Food Chem Toxicol; 2016 Nov; 97():375-384. PubMed ID: 27725205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
    Zeng J; Liu W; Fan YZ; He DL; Li L
    Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of the Antitumor Efficacy of RNAi-Mediated Inhibition of CDC20 and Heparanase in an Orthotopic Liver Tumor Model.
    Liu M; Zhang Y; Liao Y; Chen Y; Pan Y; Tian H; Zhan Y; Liu D
    Cancer Biother Radiopharm; 2015 Aug; 30(6):233-9. PubMed ID: 26132704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
    Feng B; Wang R; Chen LB
    Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics.
    Sossey-Alaoui K; Plow EF
    Mol Cancer Res; 2016 Feb; 14(2):228-38. PubMed ID: 26474967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
    Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
    Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
    Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
    Jeong CW; Yoon CY; Jeong SJ; Hong SK; Byun SS; Kwak C; Lee SE
    Urol Oncol; 2013 Nov; 31(8):1448-56. PubMed ID: 22537539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.
    Puhr M; Hoefer J; Neuwirt H; Eder IE; Kern J; Schäfer G; Geley S; Heidegger I; Klocker H; Culig Z
    Oncotarget; 2014 Dec; 5(23):12043-56. PubMed ID: 25474038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
    Crea F; Duhagon Serrat MA; Hurt EM; Thomas SB; Danesi R; Farrar WL
    Int J Cancer; 2011 Apr; 128(8):1946-54. PubMed ID: 20568112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer.
    Dyshlovoy SA; Menchinskaya ES; Venz S; Rast S; Amann K; Hauschild J; Otte K; Kalinin VI; Silchenko AS; Avilov SA; Alsdorf W; Madanchi R; Bokemeyer C; Schumacher U; Walther R; Aminin DL; Fedorov SN; Shubina LK; Stonik VA; Balabanov S; Honecker F; von Amsberg G
    Int J Cancer; 2016 May; 138(10):2450-65. PubMed ID: 26695519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
    Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
    J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
    Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer.
    Zhu S; Oremo JA; Li S; Zhen M; Tang Y; Du Y
    PLoS One; 2014; 9(3):e91817. PubMed ID: 24632829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel.
    Wen X; Li X; Liao B; Liu Y; Wu J; Yuan X; Ouyang B; Sun Q; Gao X
    Urology; 2009 Jun; 73(6):1407-11. PubMed ID: 19362342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3.
    Ding H; Sun Y; Hou Y; Li L
    Urol Oncol; 2014 Jul; 32(5):720-6. PubMed ID: 24837011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.